ISRCTN55725285 https://doi.org/10.1186/ISRCTN55725285

A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

Submission date
12/10/2004

Recruitment status
No longer recruiting

Registration date
12/10/2004

Overall study status
Completed

Last Edited
06/07/2018

Condition category
Circulatory System

[_] Prospectively registered
[X] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Cornel Pater

Contact details
Hans-Boeckler Allee 20
Hannover
Germany
30173
+49 (0)511 857 2074
cornel.pater@solvay.com

Additional identifiers

Protocol serial number
S171.3.012

Study information

Scientific Title
A novel approach to treatment of hypertension in diabetic patients - A multicenter, double-blind, randomised study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood pressure levels in patients with hypertension and associated diabetes mellitus type 2 - rationale and design.

Acronym
ASTRID (Antihypertensive treatment of Systolic/diastolic hypertension comparing Teveten and Ramipril and type 2 Diabetics)

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Primary study design
Interventional

Study design
Randomised controlled trial

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Essential Hypertension grade I and II

Interventions
Single, double- and triple- combination antihypertensive therapy, active controlled (monotherapy [eprosartan versus ramipril] followed by addition of hydrochlorothiazide as second agent and moxonidine as a third agent).

Intervention Type
Other

Phase
Not Specified

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s)
Not provided at time of registration

Completion date
01/01/2006

Eligibility

Key inclusion criteria
Investigative centers from eight European countries and Canada (primary and secondary care) targeting patients with grade I - II hypertension and associated diabetes mellitus type 2. Goal blood pressure (BP) targeted: below 130/80 mmHg.

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Not Specified

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
01/01/2004

Date of final enrolment
01/01/2006

Locations

Countries of recruitment
United Kingdom

Germany

Study participating centre
Hans-Boeckler Allee 20
Hannover
Germany
30173

Sponsor information

Organisation
Solvay Pharmaceuticals (Germany)

ROR
https://ror.org/01xscrc43

Funder(s)

Funder type
Industry

Funder Name
GPS Solvay Pharmaceuticals

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	Protocol	01/10/2004		Yes	No